# US 2024/0116889 A1 · Antiviral compounds and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0116889 A1
- Document ID: US20240116889A1
- Status: Published application
- Kind: A1
- Application number: 17/768,003
- Filed: 2020-10-07
- Published: 2024-04-11
- Earliest claimed: 2019-10-09
- Applicants: The University of Nottingham
- Inventors: Kin-Chow CHANG; Christopher James HAYES; Pavel GERSHKOVICH
- Web page: https://patentgrep.com/patent/US20240116889A1

## CPC

- C07D 307/93: condensed with a ring other than six-membered
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/215: of carboxylic acids
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/365: Lactones
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/7012: Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K31/191; ascorbic acid A61K31/375)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07C 69/24: esterified with monohydroxylic compounds
- C07C 69/533: Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C 69/675: of saturated hydroxy-carboxylic acids
- C07C 69/716: Esters of keto-carboxylic acids {or aldehydo-carboxylic acids}
- C07B 2200/07: Optical isomers
- C07C 2602/30: Azulenes; Hydrogenated azulenes
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides an agent for the treatment or prevention of viral infection in a subject. The agent is preferably a compound of Formula (I) or (Ia) wherein R1-R4, A and B are as defined herein. Also provided are pharmaceutical compositions and combinations comprising such agents.

## Claims

### Claim 1

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use in the treatment or prevention of viral infection in a subject;
wherein said thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof is formulated for oral administration, and wherein said use comprises orally administering said thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof to said subject.

### Claim 2 (depends on 1)

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to claim 1, wherein the viral infection is caused by an RNA virus.

### Claim 3 (depends on 1, 2)

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to claim 1 or claim 2, wherein the viral infection is caused by an influenza virus or a respiratory syncytial virus.

### Claim 4

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein the viral infection is caused by one or more human influenza A viruses and/or avian influenza A viruses.

### Claim 5

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use in the treatment or prevention of viral infection in a subject;
wherein said viral infection is caused by a virus of the order nidoviridae;
wherein preferably said viral infection is caused by a coronavirus, an artevirus, an okavirus, a mesonivirus or a ronivirus;
wherein more preferably the viral infection is caused by a coronavirus optionally selected from COVID-19 (SARS-coronavirus-2), Severe acute respiratory syndrome (SARS)-coronavirus, Middle East respiratory syndrome-related (MERS)-coronavirus, Human coronavirus OC43 or Human coronavirus 229E.

### Claim 6

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said use comprises administering the thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof to the subject in an amount of from about 0.01 μg/kg to about 50 μg/kg.

### Claim 7

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said use comprises administering the thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof to the subject in an amount of from about 0.1 μg/kg to about 10 μg/kg.

### Claim 8

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof is formulated in a solid oral dosage form.

### Claim 9

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof is formulated in a liquid oral dosage form.

### Claim 10

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said use comprises administering the thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof to the subject with a frequency of administration of from about one per week to about three times per day.

### Claim 11

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said use comprises administering the thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof to the subject once daily or twice daily.

### Claim 12

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said use further comprises administering an additional antiviral agent to the subject.

### Claim 13

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein the antiviral agent is selected from zanamivir, oseltamivir, peramivir, baloxavir marboxil, favipiravir, amantadine or rimantadine, or a pharmaceutically acceptable salt of any of the preceding agents.

### Claim 14

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said thapsigargin or pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof is obtainable by hydrolysis of thapsigargin, wherein said hydrolysis is preferably acid-catalysed hydrolysis.

### Claim 15

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to any one of the preceding claims, wherein said thapsigargin or pharmaceutically acceptable salt, derivative or prodrug thereof is a compound of Formula (I) or (Ia), or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof,
wherein
R1 is selected from —OH and —OC(O)RB1;
R2 is selected from H, —OH and —OC(O)RB2;
R3 is selected from —OH and —OC(O)RB3;
R4 is selected from —OH and —OC(O)RB4;
at least one of R1, R2, R3 and R4 is —OH;
RB1, RB2, RB3, and RB4 are each independently selected from unsubstituted Ci_7 alkyl and unsubstituted C2-7 alkenyl;
A is —OH and B is —OH; or A is attached to B and the moiety -A-B- is —O—.

### Claim 16 (depends on 15)

Thapsigargin, or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use according to claim 15, wherein
The compound is of Formula (II),
and/or
RB1 is
and/or
RB2 is
and/or
RB3 is —CH3; and/or
RB4

### Claim 17

A compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof, for use in the treatment or prevention of viral infection in a subject;
wherein
R1 is selected from —OH and —OC(O)RB1;
R2 is selected from H, —OH and —OC(O)RB2;
R3 is selected from —OH and —OC(O)RB3;
R4 is selected from —OH and —OC(O)RB4;
at least one of R1, R2, R3 and R4 is —OH;
RB1, RB2, RB3, and RB4 are each independently selected from unsubstituted C1-7 alkyl and unsubstituted C2-7 alkenyl;
A is —OH and B is —OH; or A is attached to B and the moiety -A-B- is —O—.

### Claim 18 (depends on 17)

A compound for use according to claim 17, wherein
said compound is of Formula (II)
and/or
RB1 is
and/or
RB2 is
and/or
RB3 is —CH3; and/or
RB4 is

### Claim 19 (depends on 17, 18)

A compound of Formula (I) or (II), or a pharmaceutically acceptable salt, stereoisomer, derivative or prodrug thereof,
wherein R1, R2, R3, R4, A and B are as defined in claim 17 or claim 18.

### Claim 20 (depends on 19)

A pharmaceutical composition comprising a compound according to claim 19 together with at least one pharmaceutically acceptable carrier or diluent.

### Claim 21 (depends on 19)

A combination comprising (i) a compound according to claim 19; (ii) an additional antiviral agent; and optionally (iii) at least one pharmaceutically acceptable carrier or diluent.

### Claim 22 (depends on 21)

A combination according to claim 21 wherein the antiviral agent is selected from zanamivir, oseltamivir, peramivir, amantadine, baloxavir marboxil, favipiravir or rimantadine, or a pharmaceutically acceptable salt of any of the preceding agents.

### Claim 23 (depends on 20, 21, 22)

A pharmaceutical composition according to claim 20 or a combination according to claim 21 or claim 22 for use in the treatment or prevention of viral infection in a subject.

### Claim 24 (depends on 17, 18)

A compound, pharmaceutical composition or combination for use according to any one of claim 17, 18, or 23, wherein the viral infection is caused by an RNA virus.

### Claim 25 (depends on 17, 18, 23, 24)

A compound, pharmaceutical composition or combination for use according to any one of claim 17, 18, 23 or 24, wherein the viral infection is caused by an influenza virus or a respiratory syncytial virus.

### Claim 26 (depends on 17, 18)

A compound, pharmaceutical composition or combination for use according to any one of claims 17, 18, or 23 to 25, wherein the viral infection is caused by one or more human influenza A viruses and/or avian influenza A viruses.

### Claim 27 (depends on 17, 18)

A compound, pharmaceutical composition or combination for use according to any one of claims 17, 18, or 23 to 24, wherein the viral infection is caused by a virus of the order nidoviridae;
wherein preferably the virus is a coronavirus, an artevirus, an okavirus, a mesonivirus or a ronivirus;
wherein more preferably the virus is a coronavirus optionally selected from COVID-19 (SARS-coronavirus-2), Severe acute respiratory syndrome (SARS)-coronavirus, Middle East respiratory syndrome-related (MERS)-coronavirus, Human coronavirus OC43 or Human coronavirus 229E.

### Claim 28 (depends on 15, 17)

A compound, pharmaceutical composition or combination for use according to any one of claims 17, 15, or 23 to 27, wherein said use comprises oral administration or pulmonary administration of the composition or combination to the subject.
